Analysis of patient survival in a Phase i trial of systemic targeted α?-therapy for metastatic melanoma

Immunotherapy

Volumn 3, Issue 9, 2011, Pages 1041-1050

  Allen, Barry J ^a,b   Singla, Apresh A ^b   Rizvi, Syed M Abbas ^a,b   Graham, Peter ^b   Bruchertseifer, Frank ^c   Apostolidis, Christos ^c   Morgenstern, Alfred ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c JOINT RESEARCH CENTRE   (Italy)

Author keywords

immunoconjugate; metastatic melanoma; Phase I trial; prognostic factors; response rates; survival; systemic therapy; toxicity

Indexed keywords

ANTIBODY CONJUGATE; LACTATE DEHYDROGENASE; RADIOISOTOPE;

AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION DOSE; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RADIOIMMUNOTHERAPY; SKIN NEOPLASMS;

EID: 80053000534     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.97     Document Type: Article

References (23)

1. Tracey E, Baker D, Chen W, Stavrou E, Bishop J. Cancer in New South Wales: incidence, mortality and prevalence report (2005).In: New South Wales Department of Health, Sydney: Cancer Institute NSW Cancer Institute NSW, NSW, Australia (2007).
2. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648 (2001). (Pubitemid 32786276)
3. Allen BJ, Raja C, Rizvi S et al. Targeted a therapy for cancer. Phys. Med. Biol. 49, 3703-3712 (2004).
4. Jurcic J, Larson S, Sgouros G et al. Targeted a particle immunotherapy for myeloid leukemia. Blood 100, 1233-1239 (2002). (Pubitemid 34864277)
5. Allen B, Blagojevic N. a-and b-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149. Nucl. Med. Comm. 17, 40-47 (1996). (Pubitemid 26079107)
6. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiation Res. 105, 27-36 (1986). (Pubitemid 16123800)
7. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiation Res. 149, 155-162 (1998). (Pubitemid 28074255)
8. Bumol TF, Reisfeld RA. Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc. Natl Acad. Sci. USA 79, 1245-1249 (1982). (Pubitemid 12105584)
9. Morgan A, Galloway D, Reisfeld R. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1, 27-33 (1982).
10. Hwang KM, Fodstad O, Oldham RK, Morgan AC Jr. Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice. Cancer Res. 45, 4150-4155 (1985). (Pubitemid 16224866)
11. Oldham RK, Foon KA, Morgan AC et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J. Clin. Oncol. 2, 1235-1244 (1984). (Pubitemid 15202697)
12. Rizvi SA, Sarkar S, Goozee G, Allen B. Radioimmunoconjugates for targeted a therapy of malignant melanoma. Melanoma Res. 10, 281-289 (2000).
13. Rizvi SMA, Qu CF, Song YJ, Raja C, Allen BJ. In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol. Therapy 4(7), 763-768 (2005). (Pubitemid 41351177)
14. Allen BJ, Raja C, Rizvi S et al. Intralesional targeted a therapy for metastatic melanoma. Cancer Biol. Therapy 4, 1318-1324 (2005). (Pubitemid 43131174)
15. Raja C, Graham P, Rizvi SMA et al. Interim analysis of toxicity and response in Phase 1 trial of systemic targeted a therapy for metastatic melanoma. Cancer Biol. therapy 6(6), 846-852 (2007). (Pubitemid 351574972)
16. Allen BJ, Raja C, Rizvi SMA, Graham P, Kearsley JH. New directions for clinical trials of targeted a therapy for metastatic melanoma. Curr. Radiopharm. 1, 240-250 (2008).
17. National Cancer Institute. Common toxicity criteria manual. In: US National Institute of Health. US NIH, USA (1999).
18. Levey A. Measurement of renal function in chronic renal disease. Kidney Int. 38, 167-184 (1990). (Pubitemid 20209447)
19. Marx GM, Blake GM, Galani E et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in 'estimating renal function in elderly cancer patients'. Ann. Oncol. 15, 291-295 (2003). (Pubitemid 38262630)
20. Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 57, 3149-3153 (1997). (Pubitemid 27351728)
21. Eton O, Legha SS, Moon TE et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J. Clin. Oncol. 16(3), 1103-1111 (1998). (Pubitemid 28108747)
22. Balch CM, Soong S-J, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622-3634 (2001). (Pubitemid 32786275)
23. Allen BJ, Raja C, Rizvi SMA, Song EY, Graham P. Tumour anti-vascular a therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys. Med. Biol. 52, L15-L19 (2007). (Pubitemid 46908610)